HK Stock Market Move | GIANT BIOGENE (02367) rose nearly 3% in the morning. Institutions point out that injectable products will become an important long-term growth engine for the company.

GIANT BIOGENE (02367) rose nearly 3% in the morning, up 2.93% to HK$54.5 as of the time of writing, with a trading volume of HK$69.3484 million. CICC International released a research report stating that considering the company's upward revision of its revenue growth guidance for 2024, which is better than the bank's previous expectations, the bank has raised the company's expected revenue compound annual growth rate for 2023-2025 to 43.5%. The report mentioned that the online GMV growth of KeFuMei and KeLiJin in 2024 is impressive. GIANT BIOGENE has raised its 2024 performance guidance, expecting revenue growth of over 50% and a net profit attributable to shareholders growth of around 40%. The bank continues to be optimistic about the rapid growth of the company's skincare line in 2025 and expects the first recombinant collagen injection product to be approved in the first quarter of this year. In December 2024, the company's medical device "recombinant collagen filler for injection for moderate to severe neck wrinkle" was granted priority approval. In addition, the registration of an injection recombinant collagen injection product for filling eye wrinkles is progressing as planned, and is expected to be approved in the first quarter of this year. The bank is confident in GIANT BIOGENE's technological advantages in the field of recombinant collagen, believing that with the company's extensive distribution network and strong brand awareness, injection products will become an important long-term growth driver for the company.